Interleukin 2 production in a family with systemic lupus erythematosus and a C4Q0 heterozygous inheritance

Carmen Gutierrez, Esther Cabrero, Jose L Vicario, Manuel Martin Villa, Miguel A Rengel, Francisco J Gomez Campdera, Miguel Yebra, Eduardo Fernandez-Cruz, Antonio Arnaiz Villena

Abstract
Interleukin 2 production was studied in a family with systemic lupus erythematosus (SLE) and a C4Q0 heterozygous inheritance. Autoimmune manifestations seemed to be associated with the HLA haplotype containing the C4Q0 allele, which was shared by all four ill family members. Concentrations of interleukin 2, however, did not associate either with the haplotype or with the clinical or serological manifestations, as diminished concentrations of interleukin 2 were found in only two subjects with SLE. Thus the defect in this family seemed to be acquired rather than genetically conditioned.

Since the pioneering descriptions of a deficient production of interleukin 2 in autoimmune animal models1 2 a series of reports have described defects in the production of interleukin 2 in response to allogeneic signals and mitogens by lymphocytes from patients with systemic lupus erythematosus (SLE).3 4 With this defect could not be corrected by addition of exogenous interleukin 14 5 and apparently did not correlate with disease activity as decreased concentrations of interleukin 2 have been found in patients with active and inactive disease.7 Other investigators have suggested that the defect may be an in vitro effect due to exhaustion of lymphocytes by excessive function in vivo.8 Furthermore, it has been suggested that low concentrations of interleukin 2 are the consequence of a compensatory mechanism to control an exaggerated T cell activation, and therefore beneficial for the patients.9 These two last hypotheses are difficult to reconcile with an increased production of B cell differentiation factor by lupus lymphocytes.7 10 11 Suppressor factors secreted by CD8 cells from lupus patients have also been reported in association with defective production of interleukin 2.12

The abnormal production of interleukin 2 in SLE may be (a) a genetically determined primary defect, (b) a collateral phenomenon associated with a generalised immunody- regulation of unknown origin; (c) secondary to clinical or serological autoimmune manifestations, or both. It has been suggested that the interleukin 2 deficiency in SLE is not a genetic trait because it may be corrected by super- induction with phorbol myristic acetate.13

Genetically determined immunoregulatory aberrations, however, may underlie the need for phorbol myristic acetate to secrete normal amounts of interleukin 2 in response to mitogens. The origin of lymphokine mediated immune dysfunction in SLE may be elucidated by a study of families with more than one member with the disease. In this report the production of interleukin 2 in several members of a family with SLE and a C4Q0 heterozygous inheritance is described.

Patients and methods
PROBAND AND FAMILY MEMBERS
The proband, a 15 year old boy who had been diagnosed with idiopathic thrombocytopenic purpura three years previously, was admitted to the Hospital Gregorio Marañon in May 1986. He had anorexia, asthenia, fever, haematuria, and severe proteinuria. The serological tests on admission yielded antinuclear antibodies at a titre of >1/640, anti-dsDNA antibodies >100 U/ml, anti-Ro antibodies 1/128, and hypocomplementaemia. A percutaneous renal biopsy showed mesangial proliferative glomerulonephritis, and a diagnosis of SLE was established. Treatment was started with oral prednisone 10 mg/day, allowing to a poor clinical response, treatment was changed to intravenous pulse methylprednisolone 15 mg/kg daily and cyclophosphamide 2 mg/kg daily. Two months later the renal function had returned to normal and treatment was continued with low doses of prednisone (20 mg/day). At the time of the study the patient was asymptomatic and was receiving 10 mg of prednisone every other day.

The proband’s mother was diagnosed as having autoimmune thrombocytopenia. She was asymptomatic at the time of the study, but laboratory tests showed thrombocytopenia and antinuclear antibodies at a titre of 1/160 with a normal platelet count. A biopsy of the skin showed a few perivascular lymphocytic infiltrates.

The proband’s father and 12 year old sister were normal. Two maternal aunts (II.1 and II.2) were studied at the Clinica Puerta de Hierro. Aunt II.1, aged 54, had probable SLE manifested by asthenia, headache, polyarthritis, muscular pain, oral ulcers, and a positive Schirmer’s test. Laboratory analysis showed antinuclear antibodies >1/640; tests for the other autoantibodies were negative. The proband’s father and 12 year old sister were normal. Two maternal aunts (II.1 and II.2) were studied at the Clinica Puerta de Hierro. Aunt II.1, aged 54, had probable SLE manifested by asthenia, headache, polyarthritis, muscular pain, oral ulcers, and a positive Schirmer’s test. Laboratory analysis showed antinuclear antibodies >1/640; tests for the other autoantibodies were negative. Complement concentrations were normal. At the time of the study she was not receiving treatment, but a few months later she showed clinical deterioration and steroid treatment (10 mg/day) was started. The other maternal aunt (II.2), aged 41, presented with malar rash, photosensitivity, polyarthralgias, headache, salivary gland swelling, xerostomia, a positive Schirmer’s test, and a salivary biopsy specimen compatible with Sjogren’s syndrome. A diagnosis of SLE and Sjogren’s syndrome was
made. The immunological tests were positive for antinuclear antibodies at a titre of 1/160 and anti-Ro antibodies at 1/128. The maternal uncle was asymptomatic and refused immunological studies. The proband's three cousins (III.1–III.3) were normal. Five healthy subjects (four female, one male, aged 20 to 42) served as controls.

SEROLOGICAL TESTS
Antinuclear antibodies were determined by standard immunofluorescence techniques using rat tissue prepared in the laboratory and commercial tumorous HEp-2 cells (Kallestad, Austin, Texas). Anti-dsDNA antibodies were detected by radioimmunoassay (Amersham International, UK), and precipitated antibodies against antigens U1RNP, Sm, Ro(SS-A), and La(SS-B) by counterimmunoelectrophoresis using a saline extract of rabbit thymus powder (Pel Frecez, Rogers, Arkansas) and an extract of human spleen prepared as previously described. Antibody specificity was defined using prototype serum samples donated by the Center for Disease Control, Atlanta, GA. C3 concentrations were determined by nephelometric analysis.

INDUCTION OF AND FUNCTIONAL ASSAY FOR INTERLEUKIN 2
Conditioned supernatants were obtained by culturing $5 \times 10^9$ peripheral blood lymphocytes in culture medium with 1% fetal calf serum and 10 μg/ml phytohaemagglutinin for 24 hours. Interleukin 2 activity in the supernatant was determined by using L2 murine cytotoxic T lymphocytes. Briefly, test supernatant or interleukin 2 standard supernatant was doubly diluted in a flat bottomed 96 well microtitre plate and $5 \times 10^3$ L2 cytotoxic T lymphocytes were added to each well. Proliferation was assayed by $[^3H]$thymidine incorporation 24 hours later. The supernatant concentration which caused half maximal $[^3H]$thymidine incorporation was defined as 1 U/ml. Values from each patient's supernatant were classified in relation to the frequency distribution of the controls. Statistical significance was determined with Student's $t$ test.

HLA TYPING
Class I and II antigens were detected by standard microlymphocytotoxicity techniques. C4 typing was carried out by electrophoresis of serum samples followed by immunofixation; Bf allele detection and C2 typing by isoelectrofocusing and immunofixation were carried out as previously described.

Results and discussion
This work was carried out in an attempt to explain the origin of the deficient production of
Interleukin 2 production in familial SLE

Interleukin 2 (IL2) production in proband and family members in relation to immunological and clinical features

<table>
<thead>
<tr>
<th>Family members</th>
<th>Clinical data</th>
<th>Treatment</th>
<th>Serological findings</th>
<th>IL2 production</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diagnosis</td>
<td></td>
<td>ANA††</td>
<td>DNA (U/ml)</td>
</tr>
<tr>
<td>Proband</td>
<td></td>
<td></td>
<td>Prendisone (20 mg/d)</td>
<td>80, H, S</td>
</tr>
<tr>
<td>Oct 1986</td>
<td>SLE†</td>
<td></td>
<td>Prendisone (10 mg alt. days)</td>
<td>160, H, S</td>
</tr>
<tr>
<td>Apr 1987</td>
<td></td>
<td></td>
<td>Prendisone (10 mg alt. days)</td>
<td>Not studied</td>
</tr>
<tr>
<td>Nov 1987</td>
<td></td>
<td></td>
<td>None</td>
<td>80, No</td>
</tr>
<tr>
<td>Father</td>
<td>Healthy</td>
<td></td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>Mother</td>
<td>Autoimmune thrombocytopenia</td>
<td></td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>Sister</td>
<td>Healthy</td>
<td></td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>Aunt II.1</td>
<td>Probable SLE</td>
<td></td>
<td>None</td>
<td>640, H</td>
</tr>
<tr>
<td>Jan 1987</td>
<td></td>
<td></td>
<td>Prendisone (10 mg/d)</td>
<td>640, H</td>
</tr>
<tr>
<td>Nov 1987</td>
<td>SLE + SS†</td>
<td></td>
<td>None</td>
<td>160, H, S</td>
</tr>
<tr>
<td>Cousin III.1</td>
<td>Healthy</td>
<td></td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>Cousin III.2</td>
<td>Healthy</td>
<td></td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>Cousin III.3</td>
<td>Healthy</td>
<td></td>
<td>None</td>
<td>0</td>
</tr>
<tr>
<td>Controls (n=5)</td>
<td></td>
<td></td>
<td>None</td>
<td>0-46 (±13)†</td>
</tr>
</tbody>
</table>

*Date of follow up visits.
†ANA=antinuclear antibodies; SLE=systemic lupus erythematosus; SS=Sjogren’s syndrome.
‡Reciprocal of the titre and fluorescence pattern. H=homogeneous; S=speckled; N=nuclear.
§Specificity of antibodies to extractable nuclear antigens. In parentheses the reciprocal of the titre.
Significant by Student’s t test; p<0.05.
¶Mean (SEM).

Interleukin 2 in subjects with SLE. With this aim major histocompatibility complex antigens and mitogen induced secretion of interleukin 2 were determined in several members of a family with SLE. The figure shows the pedigree and HLA haplotypes of this family. The table shows the concentrations of interleukin 2 induced by phytohaemagglutinin and the serological and clinical features of each family member. Un-defined genetic factors, probably linked to the genome of the proband’s mother, seemed to account for the disease process, as only the proband’s mother and her first degree relatives had autoimmune manifestations. The genetic causative agent could be associated with the HLA haplotype—A25, B18, Bw6, DRX, DQw1, DRw52, C4Aq0, C4B1, C2C, BfS, GbS—shared by all affected members and carrying the C4Q0 allele, which has been described as more prevalent among those with SLE, even if present in heterozygosity. However, two healthy members (cousins III.2 and III.3) also carried this haplotype, suggesting either that the genetic autoimmune inducing factors in this family were not linked to this haplotype, or, alternatively, that uncontrolled environmental factors contributed to the full expression of the disease. Genetic and environmental factors are probably both required for the manifestation of the illness. On the other hand, cousins III.2 and III.3 may develop autoimmune phenomena in the future as at the time of the study they were quite young—20 and 6 years of age respectively.

The table shows that three blood samples from the proband and two from aunt (II.1), both severely affected, had undetectable concentrations of interleukin 2 in a phytohaemagglutinin induced supernatant. In another affected member (aunt II.2), however, who had severe symptoms and serological alterations, including anti-Ro antibodies, the decrease in concentration of interleukin 2 was not statistically significant. In addition, the proband’s mother, who had autoimmune thrombocytopenia and who also had antinuclear antibodies, produced normal amounts of interleukin 2. All other family members behaved normally in lymphokine analysis. Attention is drawn to the fact that although the first conditioned supernatant from the proband was obtained while the patient was receiving 20 mg/day prednisone (October 1986), this was not considered to have been the case of the reduced interleukin 2 production as two subsequent samples, drawn while the patient was receiving maintenance dose of steroids (10 mg on alternate days), yielded similar results. In addition, an abnormal T cell distribution did not seem to influence the results as flow cytometric analysis showed normal relative numbers of CD4+ cells in peripheral lymphocytes of the proband and aunt II.1 (data not shown).

The above results indicate that interleukin 2 deficiency in SLE is not a genetically conditioned primary defect. If the defect were genetically determined and linked to an autoimmune trait, all affected members would be expected to synthesise low concentrations of interleukin 2. Two subjects with autoimmune disease secreted normal amounts of interleukin 2, however. Furthermore, the defect did not seem to be a consequence of autoantibody-cell antigen interactions or receptor occupancy by immune complexes as some patients secreted autoantibodies while producing interleukin 2 in normal concentrations.

Although more families should be studied before reaching a definite conclusion, our data indicate that interleukin 2 deficiency in SLE is an acquired rather than a genetic defect. Similar conclusions were obtained in a recent study of interleukin 2 production in monozygotic twins with SLE.

This work was supported by grants from the Fondo de Investigaciones Sanitarias de la Seguridad Social FSIS 85/1009 and 86/776.


Interleukin 2 production in a family with systemic lupus erythematosus and a C4Q0 heterozygous inheritance.

C Gutierrez, E Cabrero, J L Vicario, M Martin Villa, M A Rengel, F J Gomez Campderà, M Yebra, E Fernández-Cruz and A Arnaiz Villena

doi: 10.1136/ard.50.8.579

Updated information and services can be found at:
http://ard.bmj.com/content/50/8/579

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/